Tesamorelin 10mg is a growth hormone support peptide used to stimulate natural GH release, increase IGF-1 activity, and support changes in visceral fat and body composition. It is for people who want stronger GH-axis support, improved metabolic signalling, and a more advanced option for abdominal fat and recovery-focused protocols. Supplied as a 10 mg cartridge in 2 mL, it provides a structured pen-based format for evening use.
How It Works
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to the pituitary GHRH receptor and increases pulsatile growth hormone release, which in turn raises downstream IGF-1 activity. This is the basis for its effects on visceral adipose tissue, metabolic signalling, and GH-axis function. Published pharmacology and prescribing information describe tesamorelin as a GHRH analogue that increases GH and IGF-1, while clinical studies show reductions in visceral adipose tissue in the populations studied. :contentReference[oaicite:1]{index=1}
| Pathway |
Primary Effect |
| GHRH receptor |
Stimulates the pituitary to increase pulsatile GH release |
| Growth hormone output |
Supports downstream metabolic and lipolytic signalling |
| IGF-1 activity |
Increases GH-axis response and anabolic signalling |
| Visceral fat regulation |
Supports reduction in visceral adipose tissue in studied settings |
Research Findings
Human studies and prescribing information support tesamorelin most strongly for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Published studies also report increased IGF-1 response and, in some cohorts, modest reductions in liver fat. Exploratory analyses have also looked at muscle area and muscle density, but the strongest evidence remains around visceral fat and GH-axis activity. :contentReference[oaicite:2]{index=2}
| Research Area |
Observed Outcome |
| Visceral adipose tissue |
Reduction in excess abdominal visceral fat in studied populations |
| GH / IGF-1 response |
Increased GH pulsatility and higher IGF-1 activity |
| Liver fat |
Modest reduction reported in some studies |
| Body composition |
Improvement in abdominal-fat related markers and selected composition outcomes |
Dosage Protocol
Total strength: 10 mg / 2 mL
Concentration: 5 mg/mL
Pen system: 200 clicks
Per click: 0.05 mg
Timing: Evening use
Meal timing: Administer on an empty stomach, approximately 90 minutes after the last meal
Cycle guidance: Use for up to 26 weeks, then rest for 4 weeks before repeating
GH pulse duration triggered: 3–4 hours
Dose Reference Table
| Clicks / Units |
Dose (mg) |
Volume (mL) |
| 20 |
1.00 mg |
0.20 mL |
| 26 |
1.30 mg |
0.26 mL |
| 34 |
1.70 mg |
0.34 mL |
| 40 |
2.00 mg |
0.40 mL |
Beginner Titration Protocol
| Phase |
Dose Range |
Pen Equivalent |
Timing |
| Weeks 1–2 |
1.00–1.30 mg |
20–26 units |
Evening |
| Weeks 3–4 |
1.70–2.00 mg |
34–40 units |
Evening |
| Weeks 5 and beyond |
2.00 mg |
40 units |
Evening |
Protocol Notes
| Guidance |
Detail |
| Administration window |
Use at the same time in the evening to line up with natural GH pulses |
| Meal spacing |
Use on an empty stomach, about 90 minutes after the last meal |
| Cycle length |
Use for up to 26 weeks |
| Rest period |
Take a 4-week rest period before repeating |
Expected Outcomes
Tesamorelin is used where the goal is stronger GH-axis support, improved IGF-1 response, and better outcomes in visceral fat and metabolic signalling.
| Expected Outcome |
Practical Effect |
| Higher GH pulse activity |
Supports stronger endogenous growth hormone signalling |
| Increased IGF-1 output |
Supports downstream anabolic and metabolic activity |
| Visceral fat support |
Supports reduction in abdominal visceral fat markers |
| Metabolic support |
Supports body-composition and metabolic regulation goals |
| Recovery support |
May assist as part of broader GH-focused recovery protocols |
Warnings
| Warning |
Detail |
| Use timing |
Use in the evening on an empty stomach, approximately 90 minutes after the last meal |
| Dose escalation |
Beginners should follow the lower starting range before moving to 2.00 mg |
| Cycle length |
Use for up to 26 weeks, then take a 4-week rest period |
| Storage |
Keep refrigerated |
Related Products
| Product |
Use Case |
| Ipamorelin 5mg |
GH secretagogue pairing |
| CJC-1295 |
Complementary GHRH-pathway support |
| Sermorelin |
Alternative GHRH analogue option |
| BPC-157 & TB-500 |
Recovery and tissue-support pairing |
| MOTS-c |
Metabolic support pairing |
